Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced it will release its Q4 and full year 2024 financial results after market close on Monday, March 31, 2025.
The company will host a webcast/conference call at 4:30 p.m. Eastern Time on the same day, where management will discuss the results and provide a corporate update. Domestic participants can dial 1-800-717-1738, while international callers should use 1-646-307-1865 to join the teleconference.
Celcuity Inc. (Nasdaq: CELC), un'azienda biotecnologica in fase clinica focalizzata nello sviluppo di terapie oncologiche mirate, ha annunciato che rilascerà i suoi risultati finanziari del Q4 e dell'intero anno 2024 dopo la chiusura del mercato lunedì 31 marzo 2025.
L'azienda ospiterà un webcast/conferenza telefonica alle 16:30 ora orientale dello stesso giorno, durante il quale la direzione discuterà i risultati e fornirà un aggiornamento aziendale. I partecipanti nazionali possono comporre il numero 1-800-717-1738, mentre i chiamanti internazionali dovrebbero utilizzare il numero 1-646-307-1865 per partecipare alla teleconferenza.
Celcuity Inc. (Nasdaq: CELC), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias oncológicas dirigidas, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el lunes 31 de marzo de 2025.
La empresa llevará a cabo un webcast/conferencia telefónica a las 4:30 p.m. hora del Este el mismo día, donde la dirección discutirá los resultados y proporcionará una actualización corporativa. Los participantes nacionales pueden marcar el 1-800-717-1738, mientras que los llamantes internacionales deben usar el 1-646-307-1865 para unirse a la teleconferencia.
Celcuity Inc. (Nasdaq: CELC)는 표적 항암 요법 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 31일 월요일 시장 마감 후 발표할 것이라고 발표했습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 웹캐스트/전화 회의를 개최하며, 경영진이 결과를 논의하고 기업 업데이트를 제공할 예정입니다. 국내 참가자는 1-800-717-1738로 전화할 수 있으며, 국제 전화자는 1-646-307-1865를 사용하여 전화 회의에 참여해야 합니다.
Celcuity Inc. (Nasdaq: CELC), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies oncologiques ciblées, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la fermeture du marché le lundi 31 mars 2025.
L'entreprise organisera un webcast/conférence téléphonique à 16h30, heure de l'Est le même jour, où la direction discutera des résultats et fournira une mise à jour de l'entreprise. Les participants nationaux peuvent composer le 1-800-717-1738, tandis que les appelants internationaux doivent utiliser le 1-646-307-1865 pour rejoindre la téléconférence.
Celcuity Inc. (Nasdaq: CELC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung gezielter Onkologie-Therapien konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das 4. Quartal und das Gesamtjahr 2024 nach Börsenschluss am Montag, den 31. März 2025, veröffentlichen wird.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time ein Webcast/Telefonkonferenz veranstalten, in dem das Management die Ergebnisse besprechen und ein Unternehmensupdate geben wird. Inländische Teilnehmer können die Nummer 1-800-717-1738 wählen, während internationale Anrufer die Nummer 1-646-307-1865 verwenden sollten, um an der Telefonkonferenz teilzunehmen.
- None.
- None.
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1704367&tp_key=f99d4186f3. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
FAQ
When will Celcuity (CELC) release its Q4 and full year 2024 earnings?
How can investors join Celcuity's (CELC) Q4 2024 earnings call?
Will there be a replay available for Celcuity's (CELC) Q4 2024 earnings call?
What topics will be covered in Celcuity's (CELC) upcoming earnings call?
